NORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million upfront ...

AbbVie (NYSE:ABBV) has entered into a license deal with Danish biotech Gubra A/S to develop the latter’s experimental obesity treatment. GUB014295, currently in a Phase 1 clinical trial, is a ...

AbbVie will pay Gubra $350 million upfront, with up to $1.875 billion in milestone payments. GUB014295, an amylin analog for obesity, is currently in Phase 1 trials. Geopolitical tensions, Fed ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...